A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity

Part of paid clinical trials in Lenexa, Kansas.

Sponsor
Novo Nordisk A/S
Study ID
NCT07437079
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • NNC6989-0001 A — DRUG
    Participants assigned to the active intervention receive NNC6989-0001 A
  • Placebo (NNC6989-0001 A) — DRUG
    Participants assigned to the placebo, receive placebo matched in appearance to the active drug.

Study Details

This study is testing a new medicine, NNC6989-0001, to test it is safe and tolerable for healthy people living with overweight or obesity. NNC6989-0001 is still being tested in studies and is not yet available for prescription by doctors. In this study, participants will receive either NNC6989-0001 or a placebo; which treatment each participant receives will be decided by chance.

Key Dates

Start date
Feb 24, 2026
Status verified
Feb 2026
Primary completion
Jan 21, 2027
Completion
Jan 21, 2027

Study Design

Enrollment
96 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: NNC6989-0001
    Participants receive the investigational drug NNC6989-0001
  • Placebo Comparator: Placebo
    Participants receive placebo matched in appearance to the active drug.

Primary Outcome Measure

Number of treatment emergent adverse events (TEAE) - Part A [ Time Frame: From time of dosing on Day1 until completion of the end of study visit (Day 7) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
ICON Early Phase Services, LLCLenexaKansas66219-

Find similar trials in Lenexa, KS

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
ICON Early Phase Services, LLC· Lenexa, KS

Related Studies